NEOS Investment Management LLC Takes Position in Inari Medical, Inc. (NASDAQ:NARI)

NEOS Investment Management LLC acquired a new stake in shares of Inari Medical, Inc. (NASDAQ:NARIFree Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 6,100 shares of the company’s stock, valued at approximately $396,000.

Several other institutional investors have also recently modified their holdings of the company. D.A. Davidson & CO. increased its position in shares of Inari Medical by 1.8% during the 4th quarter. D.A. Davidson & CO. now owns 10,570 shares of the company’s stock valued at $686,000 after purchasing an additional 188 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of Inari Medical by 0.4% during the 4th quarter. New York State Teachers Retirement System now owns 53,924 shares of the company’s stock valued at $3,501,000 after purchasing an additional 233 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its position in shares of Inari Medical by 27.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,098 shares of the company’s stock valued at $71,000 after purchasing an additional 236 shares during the last quarter. Retirement Systems of Alabama grew its position in Inari Medical by 0.6% during the 4th quarter. Retirement Systems of Alabama now owns 64,100 shares of the company’s stock worth $4,161,000 after acquiring an additional 366 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in Inari Medical by 3.8% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 15,276 shares of the company’s stock worth $999,000 after acquiring an additional 560 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.13, for a total value of $3,007,800.00. Following the completion of the transaction, the director now owns 865,359 shares in the company, valued at approximately $43,380,446.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.13, for a total value of $3,007,800.00. Following the completion of the transaction, the director now owns 865,359 shares in the company, valued at approximately $43,380,446.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now directly owns 465,474 shares of the company’s stock, valued at approximately $23,273,700. The disclosure for this sale can be found here. Insiders sold a total of 195,964 shares of company stock worth $8,909,434 in the last quarter. 10.60% of the stock is owned by company insiders.

Inari Medical Trading Up 2.2 %

NASDAQ NARI opened at $50.35 on Thursday. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $71.85. The stock has a 50 day simple moving average of $43.82 and a two-hundred day simple moving average of $52.18.

Inari Medical (NASDAQ:NARIGet Free Report) last released its earnings results on Tuesday, April 30th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). The firm had revenue of $143.19 million during the quarter, compared to analysts’ expectations of $138.32 million. Inari Medical had a negative net margin of 4.54% and a negative return on equity of 1.65%. On average, sell-side analysts expect that Inari Medical, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wells Fargo & Company reduced their price target on Inari Medical from $100.00 to $84.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 1st. Truist Financial reduced their price target on Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a research report on Friday, March 22nd. Needham & Company LLC reduced their price target on Inari Medical from $72.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Canaccord Genuity Group reduced their price target on Inari Medical from $75.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Finally, Piper Sandler dropped their price objective on Inari Medical from $55.00 to $50.00 and set a “neutral” rating for the company in a report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.71.

View Our Latest Report on Inari Medical

About Inari Medical

(Free Report)

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

Further Reading

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.